WntResearch AB

Equities

WNT

SE0022239901

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET Other stock markets 23:00:00 06/06/2024 BST			5-day change	1st Jan Change
10.3 ^SEK	+1.48%		-0.58%	+11.96%

05-03	WntResearch AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02-29	WntResearch AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

WntResearch AB Announces Appointment of Pernilla Sandwall as the New CEO

June 27, 2022 at 08:32 am

Pernilla Sandwall took over the helm as the new CEO of WntResearch a little more than a month ago. She joins the company during a very interesting time, ahead of interim results from the phase II study NeoFox that are expected in the fourth quarter.

Latest news about WntResearch AB

WntResearch AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-03	CI
WntResearch AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-29	CI
WntResearch AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
WntResearch Initiates Collaboration with Business Sweden with the Goal of Establishing Commercial Partnerships for Foxy-5 in Japan and South Korea	02-26	CI
WntResearch AB Continues to the Next Step in the Phase 2 Study Neofox with the Highest Evaluated Dose of Foxy-5	02-12	CI
WntResearch Announces CEO Changes	01-09	CI
WntResearch Continues to the Second Dose Group in Clinical Proof of Concept Study of Foxy-5	12-06	CI
WntResearch AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-16	CI
WntResearch AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	17/08/23	CI
Certain Shares of WntResearch AB are subject to a Lock-Up Agreement Ending on 16-JUL-2023.	15/07/23	CI
WntResearch AB Announces New Study Plan Approves for Wnt Research's Phase II Study	14/07/23	CI
WntResearch AB Reports Earnings Results for the First Quarter Ended March 31, 2023	04/05/23	CI
WntResearch AB Reports Earnings Results for the Full Year Ended December 31, 2022	09/02/23	CI
WntResearch AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	09/02/23	CI
WntResearch AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	17/11/22	CI
WntResearch AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	18/08/22	CI
WntResearch AB Announces Appointment of Pernilla Sandwall as the New CEO	27/06/22	CI
WntResearch AB Reports Earnings Results for the First Quarter Ended March 31, 2022	05/05/22	CI
WntResearch Announces Appointment of Pernilla Sandwall as CEO	13/02/22	CI
WntResearch AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021	09/02/22	CI
WntResearch files a patent application for the treatment of Acute Myeloid Leukemia	13/12/21	CI
WntResearch AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	17/11/21	CI
WntResearch : to Look for New CEO as Acting Chief Steps Down	09/09/21	MT
Anders Rabbe Decides to Move on from Wntresearch AB	09/09/21	CI
WntResearch AB Announces Update on Patient Recruitment for the Ongoing Phase IIa Clinical Study Neofox with Wntresearch's Drug Candidate Foxy-5	14/04/21	CI

Chart WntResearch AB

Duration

Period

More charts

Company Profile

WntResearch AB is a Sweden-based company engaged in the translational cancer research. Its aim is to develop anti-metastatic therapies based on an increased understanding of the mechanisms underlying the metastatic process and the evaluation of specific small molecules that can specifically interact with this process. The Companyâs programs focus on the role of the Wnt-5a protein in the metastatic process. As of December 31, 2011, the Company had two projects, namely Foxy-5 and Box-5. Foxy-5 is a hexapeptide mimicking the effects of WNT-5a. Box-5 is a peptide antagonizing the effects of Wnt-5a. As of March 31, 2012, the Companyâs largest shareholder was Forskarpatent I Syd AB, which held 26.55% shares.

Sector

Biotechnology & Medical Research

Calendar

21/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
WNTRESEARCH AB	+11.96%	8.45M
VERTEX PHARMACEUTICALS INCORPORATED	+18.72%	125B
REGENERON PHARMACEUTICALS, INC.	+14.19%	108B
BIONTECH SE	-4.93%	24.57B
ARGENX SE	+3.23%	22.82B
GENMAB A/S	-10.44%	18.19B
WUXI APPTEC CO., LTD.	-41.74%	16.54B
BEIGENE, LTD.	-13.31%	16.5B
NEUROCRINE BIOSCIENCES, INC.	+2.44%	13.39B
SAREPTA THERAPEUTICS, INC.	+27.89%	11.1B

Bio Therapeutic Drugs